Cargando…
Management of Myelofibrosis during Treatment with Ruxolitinib: A Real-World Perspective in Case of Resistance and/or Intolerance
The development and approval of ruxolitinib, the first JAK1/2 inhibitor indicated to treat myelofibrosis, has improved patient outcomes, with higher spleen and symptoms responses, improved quality of life, and overall survival. Despite this, several unmet needs remain, including the absence of resis...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9325304/ https://www.ncbi.nlm.nih.gov/pubmed/35877255 http://dx.doi.org/10.3390/curroncol29070395 |
_version_ | 1784757016953094144 |
---|---|
author | Breccia, Massimo Palandri, Francesca Guglielmelli, Paola Palumbo, Giuseppe Alberto Malato, Alessandra Mendicino, Francesco Ricco, Alessandra Sant’Antonio, Emanuela Tiribelli, Mario Iurlo, Alessandra |
author_facet | Breccia, Massimo Palandri, Francesca Guglielmelli, Paola Palumbo, Giuseppe Alberto Malato, Alessandra Mendicino, Francesco Ricco, Alessandra Sant’Antonio, Emanuela Tiribelli, Mario Iurlo, Alessandra |
author_sort | Breccia, Massimo |
collection | PubMed |
description | The development and approval of ruxolitinib, the first JAK1/2 inhibitor indicated to treat myelofibrosis, has improved patient outcomes, with higher spleen and symptoms responses, improved quality of life, and overall survival. Despite this, several unmet needs remain, including the absence of resistance criteria, suboptimal response, the timing of allogeneic transplant, and the management of patients in case of intolerance. Here, we report the results of the second survey led by the “MPN Lab” collaboration, which aimed to report physicians’ perspectives on these topics. As in our first survey, physicians were selected throughout Italy, and we included those with extensive experience in treating myeloproliferative neoplasms and those with less experience representing clinical practice in the real world. The results presented here, summarized using descriptive analyses, highlight the need for a clear definition of response to ruxolitinib as well as recommendations to guide the management of ruxolitinib under specific conditions including anemia, thrombocytopenia, infections, and non-melanoma skin cancers. |
format | Online Article Text |
id | pubmed-9325304 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-93253042022-07-27 Management of Myelofibrosis during Treatment with Ruxolitinib: A Real-World Perspective in Case of Resistance and/or Intolerance Breccia, Massimo Palandri, Francesca Guglielmelli, Paola Palumbo, Giuseppe Alberto Malato, Alessandra Mendicino, Francesco Ricco, Alessandra Sant’Antonio, Emanuela Tiribelli, Mario Iurlo, Alessandra Curr Oncol Article The development and approval of ruxolitinib, the first JAK1/2 inhibitor indicated to treat myelofibrosis, has improved patient outcomes, with higher spleen and symptoms responses, improved quality of life, and overall survival. Despite this, several unmet needs remain, including the absence of resistance criteria, suboptimal response, the timing of allogeneic transplant, and the management of patients in case of intolerance. Here, we report the results of the second survey led by the “MPN Lab” collaboration, which aimed to report physicians’ perspectives on these topics. As in our first survey, physicians were selected throughout Italy, and we included those with extensive experience in treating myeloproliferative neoplasms and those with less experience representing clinical practice in the real world. The results presented here, summarized using descriptive analyses, highlight the need for a clear definition of response to ruxolitinib as well as recommendations to guide the management of ruxolitinib under specific conditions including anemia, thrombocytopenia, infections, and non-melanoma skin cancers. MDPI 2022-07-15 /pmc/articles/PMC9325304/ /pubmed/35877255 http://dx.doi.org/10.3390/curroncol29070395 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Breccia, Massimo Palandri, Francesca Guglielmelli, Paola Palumbo, Giuseppe Alberto Malato, Alessandra Mendicino, Francesco Ricco, Alessandra Sant’Antonio, Emanuela Tiribelli, Mario Iurlo, Alessandra Management of Myelofibrosis during Treatment with Ruxolitinib: A Real-World Perspective in Case of Resistance and/or Intolerance |
title | Management of Myelofibrosis during Treatment with Ruxolitinib: A Real-World Perspective in Case of Resistance and/or Intolerance |
title_full | Management of Myelofibrosis during Treatment with Ruxolitinib: A Real-World Perspective in Case of Resistance and/or Intolerance |
title_fullStr | Management of Myelofibrosis during Treatment with Ruxolitinib: A Real-World Perspective in Case of Resistance and/or Intolerance |
title_full_unstemmed | Management of Myelofibrosis during Treatment with Ruxolitinib: A Real-World Perspective in Case of Resistance and/or Intolerance |
title_short | Management of Myelofibrosis during Treatment with Ruxolitinib: A Real-World Perspective in Case of Resistance and/or Intolerance |
title_sort | management of myelofibrosis during treatment with ruxolitinib: a real-world perspective in case of resistance and/or intolerance |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9325304/ https://www.ncbi.nlm.nih.gov/pubmed/35877255 http://dx.doi.org/10.3390/curroncol29070395 |
work_keys_str_mv | AT brecciamassimo managementofmyelofibrosisduringtreatmentwithruxolitinibarealworldperspectiveincaseofresistanceandorintolerance AT palandrifrancesca managementofmyelofibrosisduringtreatmentwithruxolitinibarealworldperspectiveincaseofresistanceandorintolerance AT guglielmellipaola managementofmyelofibrosisduringtreatmentwithruxolitinibarealworldperspectiveincaseofresistanceandorintolerance AT palumbogiuseppealberto managementofmyelofibrosisduringtreatmentwithruxolitinibarealworldperspectiveincaseofresistanceandorintolerance AT malatoalessandra managementofmyelofibrosisduringtreatmentwithruxolitinibarealworldperspectiveincaseofresistanceandorintolerance AT mendicinofrancesco managementofmyelofibrosisduringtreatmentwithruxolitinibarealworldperspectiveincaseofresistanceandorintolerance AT riccoalessandra managementofmyelofibrosisduringtreatmentwithruxolitinibarealworldperspectiveincaseofresistanceandorintolerance AT santantonioemanuela managementofmyelofibrosisduringtreatmentwithruxolitinibarealworldperspectiveincaseofresistanceandorintolerance AT tiribellimario managementofmyelofibrosisduringtreatmentwithruxolitinibarealworldperspectiveincaseofresistanceandorintolerance AT iurloalessandra managementofmyelofibrosisduringtreatmentwithruxolitinibarealworldperspectiveincaseofresistanceandorintolerance |